Nationwide registry- based analysis of cardiovascular risk factors and adverse outcomes in patients treated with stronium ranelate

In conclusion, baseline cardiovascular diseases are common in patients treated with strontium ranelate, with more than half of strontium ranelate users being current

users of antiplatelet drugs or having a history of cerebrovascular disease, peripheral vascular disease or myocardial infarction. Moreover, this observational study shows an increased confounder-adjusted mortality risk in patients treated with strontium ranelate compared with other osteoporosis drugs.